Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

INGN-241. Introgen.

Rahul Gopalkrishnan1

  • 1Columbia University, College of Physicians and Surgeons, Department of Pathology, Box 23 BB 1505, 630 West 168 Street, New York, NY 10032, USA. rg285@columbia.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Introgen is developing INGN-241, a novel gene therapy utilizing the mda-7 gene and an adenoviral vector, for cancer treatment. A Phase I clinical trial investigating its efficacy in solid tumors began in late 2000.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Introgen is developing INGN-241, a gene therapy product.
  • INGN-241 is based on the mda-7 gene.
  • It utilizes an adenoviral delivery system licensed from Corixa (formerly GenQuest).

Purpose of the Study:

  • To evaluate the potential of INGN-241 as a cancer treatment.
  • To assess the safety and tolerability of INGN-241 in a Phase I trial.

Main Methods:

  • INGN-241 combines the mda-7 gene with an adenoviral vector.
  • A Phase I clinical trial was initiated.
  • The trial focuses on patients with solid tumors.

Main Results:

  • The Phase I trial for INGN-241 was initiated in late November 2000.

Related Experiment Videos

Conclusions:

  • INGN-241 represents a novel approach to cancer therapy using gene modification.
  • Further clinical evaluation is warranted to determine its therapeutic potential.